Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis

Journal of Clinical Apheresis

Volumn 26, Issue 6, 2011, Pages 326-331

  Fukunaga, Ken ^a   Kamikozuru, Koji ^a   Yokoyama, Yoko ^a   Hida, Nobuyuki ^a   Ohda, Yoshio ^a   Takeda, Naohisa ^a   Yoshida, Koji ^a   Iimuro, Masaki ^a   Kikuyama, Risa ^a,b   Kato, Kyoichi ^a   Nagase, Kazuko ^a   Nakamura, Shiro ^a   Miwa, Hiroto ^a   Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse event; Apheresis blood volume; Inflammatory bowel disease; Leukocytapheresis; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; PREDNISOLONE;

ADULT; AGED; ARTICLE; BLOOD VOLUME; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPLICATION; CONTROLLED STUDY; CYTAPHERESIS; FEMALE; HUMAN; LEUKOCYTAPHERESIS; MALE; PROSPECTIVE STUDY; SAFETY; SCHOOL CHILD; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 83555162465     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20314     Document Type: Article

References (25)

1. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR,. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005; 11: S3-S12. (Pubitemid 41572703)
2. Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T,. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003; 9: 307-321. (Pubitemid 36131725)
3. Sawada K, Ohnishi K, Fukui S, Yamada K, Yamamura M, Amano K, Wada M, Tanida N, Satomi M, Shimoyama T,. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 1995; 30: 322-329.
4. Allison MC, Dhillon AP, Lewis WG, editors. Inflammatory bowel disease. London: Mosby; 1998. pp 9-95.
5. Matsumoto T, Andoh A, Okawa K, Ito H, Torii A, Yoshikawa S, Nakaoka R, Okuyama Y, Oshitani N, Nishishita M, Watanabe K, Fukunaga K, Ohnishi K, Kusaka T, Yokoyama Y, Sasaki M, Tsujikawa T, Aoki T, Kusaka T, Takeda Y, Umehara Y, Nakamura S, Fujiyama Y,. Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study. Ther Apher Dial 2008; 12: 484-490.
6. Muratov V, Lundahl J, Mandic-Havelka A, Elvin K, Ost A, Shizume Y, Furuya K, Löfberg R,. Safety and tolerability of a modified filter-type device for leukocytapheresis using ACA-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study. J Clin Apher 2010; 25: 287-293.
7. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR,. Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001; 16: 1-9.
8. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-1629. (Pubitemid 18010466)
9. Shirokaze J,. Leukocytapheresis using a leukocyte removal filter. Ther Apher 2002; 6: 261-266.
10. Rachmilewitz D,. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-86. (Pubitemid 19032930)
11. Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T,. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009; 104: 2990-2995.
12. Yamaji K, Onuma S, Yasuda M, Kanai Y, Tsuda H, Takasaki Y,. Fluctuations in peripheral blood leukocyte and platelet counts and leukocyte recruitment with large volume leukocytapheresis in healthy volunteers. Ther Apher Dial 2006; 10: 396-403. (Pubitemid 44652199)
13. Shimada M, Iwase H, Tsuzuki T, Hirashima N, Kobayashi K, Hibino Y, Watanabe H, Ryuge N, Ando T, Goto H, Yagi Y, Tsujikawa T, Andoh A,. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis. Ther Apher Dial 2008; 12: 368-373.
14. Sawada K, Kusugami K, Sukuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T,. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-controlled study with sham apheresis as placebo treatment. Am J Gastroenterol 2005; 100: 1362-1369. (Pubitemid 40904363)
15. Nishioka C, Aoyama N, Maekawa S, Shirasaka D, Nakahara T, Tamura T, Fukagawa M, Umezu M, Abe T, Kasuga M,. Leukocytapheresis therapy for steroid-naîve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol 2005; 20: 1567-1571. (Pubitemid 43961112)
16. Ashida T, Kohgo Y, Munakata A, Noguchi M, Iizuka B, Endo Y, Hanai H, Yoshikawa T, Matsumoto T, Aoyama N, Matsui T, Mitsuyama K, Hibi T,. A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis. Transfus Apher Sci 2011; 44: 113-117.
17. Kosaka T, Sawada K, Ohnishi K, Egashira A, Yamamura M, Tanida N, Satomi M, Shimoyama T,. Extracorporeal elimination of TNF-alpha-producing CD14(dull)CD16(+) monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm Bowel Dis 2007; 13: 284-290.
18. Kanai T, Makita S, Kawamura T, Nemoto Y, Kubota D, Nagayama K, Totsuka T, Watanabe M,. Leukocytapheresis therapy modulates circulating t cell subsets in patients with ulcerative colitis. Ther Apher Dial 2005; 9: 270-276.
19. Andoh A, Tsujikawa T, Inatomi O, Deguchi Y, Sasaki M, Obata H, Mitsuyama K, Fujiyama Y,. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol 2006; 41: 524-532.
20. Fukunaga K, Fukuda Y, Yokoyama Y, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T,. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Intern Med 1999; 38: 102-111.
21. Yagi Y, Andoh A, Inatomi O, Bamba S, Tsujikawa T, Fujiyama Y, Mitsuyama K, Yoshida T,. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol 2006; 41: 540-546. (Pubitemid 44138195)
22. Tsujikawa T, Andoh A, Ogaẃa A, Sonoda A, Yagi Y, Hata K, Sasaki M, Saito Y, Fujiyama Y,. Feasibility of five days of consecutive leukocytapheresis for the treatment of ulcerative colitis: a preliminary study. Ther Apher Dial 2009; 13: 14-18.
23. National health and nutrition examination survey; Final report of findings. Centers for Disease Control and Prevention, available at: http://www.cdc.gov/nchs/data/nhanes/nhanes-07-08/ROF-07-08-eng.pdf. Accessed March 22, 2011.
24. Annual report of the survey for health and nutrition in the citizen 2009, Ministry of Health, Labor and Welfare, available at: http://www.mhlw.go.jp/ houdou/2009/11/h1109-1.html [Japanese] Accessed March 22, 2011.
25. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S,; Adacolumn Study Group. Arandomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008; 135: 400-409.